Hemogenyx Pharmaceuticals PLC Hemogenyx Welcomes N.Y. Lt. Governor to its Labs
11 January 2018 - 6:00PM
RNS Non-Regulatory
TIDMHEMO
Hemogenyx Pharmaceuticals PLC
11 January 2018
Hemogenyx Pharmaceuticals Plc
("Hemogenyx" or the "Company")
Hemogenyx Welcomes N.Y. Lt. Governor to its Labs
Advanced biotech startup touts ground-breaking medical research,
deep ties to New York State.
Hemogenyx Pharmaceuticals Plc (LSE: HEMO), the biotechnology
company developing novel therapies to transform bone marrow, or
blood stem cell, transplantation for the treatment of blood
diseases, welcomed New York Lieutenant Governor Kathy Hochul to its
labs at the SUNY Downstate Medical Center Biotech Incubator.
In addition to showing Hochul its cutting-edge facilities,
Hemogenyx also briefed the Lieutenant Governor on its advanced
technologies-and their potential to save lives.
"As a biotech company with its roots in New York, we were
honored to welcome Lieutenant Governor Hochul to our labs," said
Dr. Vladislav Sandler, CEO of Hemogenyx. Hemogenyx, which went
public last year on the London Stock Exchange, opened its first lab
in Buffalo after winning the New York-state funded 43North business
competition. Now its four scientists work out of two
state-of-the-art labs inside SUNY Downstate Medical Center's
Biotech Incubator. "Having access to the high-quality facilities at
SUNY Downstate has been instrumental to our success in creating a
safer and more effective approach to bone marrow transplants,"
added Dr. Sandler.
"By providing biotech businesses with state-of-the-art
laboratory space and financial support in the early stages, the
SUNY Downstate Biotech Incubator is setting them up with the tools
they need to grow into our next entrepreneurial success stories,"
said Lieutenant Governor Hochul. "Hemogenyx Pharmaceuticals is one
such success story, launching their business in New York State with
the 43 North Startup competition and continuing to expand at SUNY
Downstate's world-class facilities."
Hochul's visit to Hemogenyx was part of a larger tour of the
SUNY Downstate Biotech Incubator. After seeing the facility, the
Lieutenant Governor gave a special presentation of Governor Cuomo's
State of the State address.
Enquiries:
Hemogenyx Pharmaceuticals Limited www.hemogenyx.com
Dr Vladislav Sandler, Chief Via Walbrook PR
Executive Officer & Co-Founder
Dr Robin Campbell, Chairman
Optiva Securities Ltd Tel: +44 (0)20 3137 1902
Christian Dennis
Shard Capital Partners LLP Tel: +44 (0)20 7186 9950
Damon Heath, Erik Woolgar
Peterhouse Corporate Finance Tel: +44 (0)20 7469 0930
Limited
Lucy Williams/Duncan Vasey
Walbrook PR (UK Media & Tel: +44 (0)20 7933 8780 or
Investor Relations) hemogenyx@walbrookpr.com
Paul McManus Mob: +44 (0)7980 541 893
US Media enquiries
Lowell Goodman Tel: +1 (323) 646-3249 or lowell@lowellgoodman.net
About Hemogenyx Pharmaceuticals Plc
Hemogenyx Pharmaceuticals Plc is a publicly traded company (LSE:
HEMO) headquartered in London, with its wholly owned U.S. operating
subsidiary, HemoGenyx LLC, located in its state-of-the-art research
facility in Brooklyn, New York.
HemoGenyx is a preclinical-stage biopharmaceutical company
focused on the discovery, development and commercialization of
novel therapies and treatments for blood diseases such as leukemia
and lymphoma. The company's leading technologies aim to change the
way in which bone marrow/hematopoietic stem cell (BM/HSC)
transplants are performed and improve their efficacy. HemoGenyx's
two distinct and complementary products include an immunotherapy
product for patient conditioning-the CDX bi-specific antibody-and a
cell therapy product for BM/HSC transplantation-the HuPHEC. Each of
these products holds the potential to revolutionize the way BM/HSC
transplants are being performed, offering solutions that mitigate
the dangers and limitations associated with the current standard of
care.
For more information, visit www.hemogenyx.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAGGUMUGUPRPPU
(END) Dow Jones Newswires
January 11, 2018 02:00 ET (07:00 GMT)
Silver Falcon (LSE:SILF)
Historical Stock Chart
From Apr 2024 to May 2024
Silver Falcon (LSE:SILF)
Historical Stock Chart
From May 2023 to May 2024